Allergan Pitches Cost-Cutting Plan In Continued Defense Of Valeant Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan continued to fend off Valeant during its second quarter earnings call by announcing a plan to save $475 million over the next five years, which includes 1,500 job cuts. Valeant bit back by complaining to the SEC.